Apart from reinforcing previous studies our data highlight the increased susceptibility of CFTR heterozygous to developing CP. Heterozygosity combined with other factors puts these individuals at greater risk.
INTRODUCTION
Chronic pancreatitis (CP) is a persistent inflammatory process of the pancreas characterized by irreversible destruction of pancreatic structure and loss of its function. The diagnosis of CP is currently based on clinical symptoms and on morphological and functional alterations. 1 Whereas some environmental factors, mainly excessive alcohol consumption, are associated with it, little is known about other factors involved in the pathogenic mechanism of the disease. The abuse of alcohol consumption is related to a high proportion (65-80%) of CP. In contrast, only a minority of alcoholics (5-10%) develops CP, 2 suggesting that alcohol abuse is a predisposing factor but not a unique one. On the other hand, an important group of patients suffering CP (10-30%) has an unknown etiology, classified as idiopathic.
Mutations in the CFTR gene (MIM#602421) 3 are responsible for cystic fibrosis (CF) disease (MIM#219700), a hereditary recessive disorder affecting 1 in 2000-4000 newborns in the Caucasian population. The main characteristics of clinical CF features are chronic lung disease, pancreatic insufficiency and male infertility, associated with a high electrolyte concentration in sweat. 4 The CFTR protein 5 is a cAMP-regulated channel which controls chloride and water transport, as well as other ion channels across the apical membrane of the epithelial cells. In pancreatic duct cells, the CFTR protein regulates chloride, bicarbonate and sodium exchange.
Consequently, CFTR dysfunction leads to an alteration of the pancreatic juice, which results in reduced alkaline concentration and dehydrated composition. The decreased enzyme secretion and the formation of protein plugs cause obstruction of the duct lumen and progressive exocrine pancreatic insufficiency. 6 Eighty-five per cent of CF patients show steatorrhea and need enzyme supplementation. Among CF patients the prevalence of pancreatitis is low, it is estimated at around 2% and mainly defined as acute recurrent pancreatitis. 7 Controversial results on CFTR mutations in chronic and acute pancreatitis were previously reported by several authors, [8] [9] [10] [11] [12] [13] [14] probably due to differences in the final diagnosis of patients as well as the fact that a greater part of the studies were focused in the common CF gene mutations.
In order to provide more data that could elucidate the role of the CFTR mutations in the pathogenesis of CP we have performed the CFTR gene analysis of all 27 coding regions and flanking intronic sequences in a cohort of 68 CP patients. Under these criteria, 68 patients (54 males and 14 females) were enrolled to CFTR gene analysis. Furthermore, regarding the etiology, patients were classified in two groups: Group I comprised 37 patients diagnosed of alcoholic chronic pancreatitis (ACP). In this group alcohol consumption was considered to be the responsible etiology when ethanol intake exceeded 60g/day for at least 5 years before the onset of pancreatitis. All patients were males except one, the mean age was 51 (range and the alcohol consumption ranged from 6 to 30 years. Group II comprised 31
MATERALS AND METHODS

Subjects
patients with the diagnosis of idiopathic chronic pancreatitis (ICP). In this group alcohol consumption was absolutely discarded and confirmed the absence of any other disease associated risk factors. In one patient with primary sclerosing cholangitis, CP was confirmed with secretin-CCK test and histopathological features. The patients were 18 males and 13 females with a mean age of 53 years (range 9-82). The wide age range was attributable to early-onset of symptoms (before 35 years old) found in 25% of patients.
All patients in this study were unrelated and without family history of CF or pancreatitis. The Ethical Committee of each Hospital approved the study.
Clinical study
Pancreatic disease study included, whenever possible to record, time evolved since the diagnosis, body mass index, alcohol and years of consumption, tobacco smoking, clinical, morphological and functional pancreatic features (acute pancreatitis, pain, pseudocysts, calcifications, diabetes mellitus, exocrine pancreatic insufficiency), enzyme replacement therapy and presence of concomitant hepatobiliary disease.
In addition, clinical features of CF were investigated in available patients.
Lung function was evaluated by FEV1 (forced expiratory volume in 1 second) % predicted and FVC (forced vital capacity) % predicted. Sputum cultures, sweat test using the Wescor Macroduct System (Sweat check, Wescor Inc, USA) and questions relating to offspring were also recorded.
CFTR gene analysis
The DNA was extracted from peripheral blood using standard protocols (Wizard ® Genomic DNA Purification kit, Promega Corporation, Madison, USA). The complete 27 coding regions and exon/intron boundaries of the CFTR gene were analyzed in all patients using two screening techniques, multiplex denaturing gradient gel electrophoresis (DGGE) 16 18 were performed.
Additionally, the mutational spectrum found in chronic pancreatitis patients was compared with our series of CF patients, 17 congenital bilateral absence of the vas deferens (CBAVD) patients 19 and the general population (n = 41).
20
Statistical analysis
Continuous variables from the groups studied and the statistical significance differences applying the Fisher's exact 2-tailed test to compare distributions of categorical variables were analyzed with the software package SPSS 10.0 Inc., Chicago, IL. P values < 0.05 were considered to indicate statistical significance. Figure 1 ). The most common mutation in the CFTR gene, F508del, was found in 3 ACP patients (8%) but it was absent in the ICP group. Another common CF mutation, W1282X was identified in 1 ACP patient.
RESULTS
Mutational
In contrast, the 1716G/A variant displayed the highest frequency (13%) in this study as it was being detected in 22.6% of ICP patients. The 1716G/A variant modified the splice site consensus sequence determining the skipping of exon 10. The frequency in the ICP group was nearly twice that found in the general population (12%) and four times that detected in the ACP group (5.4%). However, no significant differences were found between the three groups (ACP, ICP and general population). Also, two missense mutations/variants, the R668C and L997F were detected in both CP groups.
The R668C was found isolated in one ACP patient and as the complex allele D443Y+G576A+R668C (common in CBAVD) in one ICP patient.
The 5T variant was identified in 5 patients (7.3%) (3 ACP, 8% and 2 ICP, 6%), showing no significant difference from the general population (9.4%). The 5T-12TG-V470 haplotype, which results in a lower level of functional CFTR protein, was identified in one unique ACP patient (Table 1) .
Three patients showed two changes. Although no familial studies were performed, taking into account our cohort of CF families and CBAVD patients, we assumed that the three patients (4%) would be compound heterozygous ( Clinical characteristics of 68 CP patients are shown in Table 2 . When all patients were considered, we found that episodes of acute pancreatitis (P = 0.005),
abdominal pain (P = 0.02), tobacco and pancreatic calcifications (P < 0.001) and pancreatic pseudocysts (P = 0.002) showed significantly higher values in ACP than ICP. However, within each group, no significant differences were found between patients with and without mutations in any of the parameters evaluated.
The clinical characteristics of CF disease were also evaluated. As a consequence of the chronic pancreatic damage, about 50% of the patients had developed pancreatic insufficiency and diabetes mellitus (Tables 1, 2 
DISCUSSION
We have analyzed the CFTR gene in a cohort of 68 clinically well defined CP patients in order to investigate the contribution of the CFTR mutations in this pancreatic disease.
Sixteen mutations/variants located along the gene were identified in 40% of ACP and 39% of ICP patients, most of them being rare mutations. Curiously, the mutational spectrum differs between ACP and ICP. Common CF mutations, F508del
and W1282X, were found exclusively in ACP (11%). Taking into account the frequencies of these mutations in Spanish CF patients, 53% and 0.8% respectively 17 and assuming a 4% of CF carriers in the general population, we would expect around 2% of carriers for these CF mutations. Consequently, the carrier frequency for F508del and W1282X mutations was five times increased in ACP, although statistical significance was not found. On the other hand, the 1716G/A variant, which determines the skipping of exon 10, 21 proved to be the most frequent (22%) in ICP group. This variant was previously reported in recurrent acute pancreatitis 10 and CP. 12 Interestingly, the consequence of the 1716G/A variant (exon 10 skipping) could be compared to that of the 5T variant (exon 9 skipping) as both affect the NBF1 domain and produce incomplete CFTR protein. Our results suggest that the 1716G/A variant could be a predisposing factor to CP, as well as the L997F mutation, that was found associated with idiopathic pancreatitis and neonatal hypertrypsinemia. 22 In our cohort of patients, the L997F mutation was detected in both groups (3%).
Controversial data has been reported on ACP after the analysis of the most common CF mutations, 9, 11, 23, 24 whereas Norton et al. suggested that CFTR mutations
were not a predisposing factor to pancreatitis, other authors identified mutations in 8-18% of patients. The differences in the molecular analysis could explain our higher frequency (40%). The 5T variant analysis led to their exclusion as a predisposing factor of ACP. 24, 25 We have identified the 5T variant in 8% of ACP patients, that was a similar frequency to that found in our previous study (10.5%) 26 and in the general population (9.4%). Furthermore, the 5T-12TG-V470 haplotype that shows high specificity with the CBAVD phenotype 27 was identified in only one patient.
The involvement of CFTR mutations in ICP has been unanimously accepted. [8] [9] [10] [11] [12] [13] [14] Moreover, Noone et al. postulated that ICP and CBAVD phenotypes have similar CFTR gene characteristics. However, we found important molecular differences between these two phenotypes. First, the 5T variant frequency that ranges from 6% in ICP to 43% in CBAVD patients. 19 No patients with the 5T variant displayed another CFTR change when this genotype, CFTR / 5T, is the most frequent in CBAVD.
Moreover, variable splice efficiency from the 5T variant had been observed in different tissues, indicating that its disease expression was more severe in vas deferens than others. 28, 29 The second discrepancy is due to the sensibility of the CFTR screening techniques. The size of the CFTR gene (230kb) and the fact that most mutations affect only one or a few nucleotides (point mutations) have led to the implementation of screening techniques, such as DGGE and SSCA that have a high sensibility to these changes (97% in CF Spanish patients) (unpublished data). Using this gene analysis strategy, we identified 16 mutations, mainly uncommon, in 39% of ICP patients, only one of them being compound heterozygous (3%). These frequencies are far from those reported in the CBAVD patients, in whom mutations were identified in 85% of CBAVD, 56% being compound heterozygous. 19 Five of the clinical parameters analyzed showed differences with statistical significance between alcoholic and idiopathic groups. These differences could be due to an earlier age of onset and the longest evolution time of the CP in the alcoholic group. No other statistical differences were found between the two groups, neither between patients with or without mutations. The lack of clinical differences is not rare as pancreatitis results from the combined effect of different predisposing risk factors masking the effect of each specific one.
It was seen that CFTR expression is not ubiquitous; higher CFTR levels have been shown in the pancreas and other gastrointestinal fetal tissues than elsewhere. 30 In fact, most of the CF patients present pancreatic insufficiency from an early age.
These findings point to the fact that CFTR function must be essential to prevent gastrointestinal disease. Although we cannot exclude a mutation in another region that could increase the proportion of mutant genes, our data supports a higher carrier frequency (35%) among CP patients than expected. Predictably, the CFTR mutations 
ABSTRACT
While all patients with cystic fibrosis (CF) have mutations in both CFTR
alleles, often only one CFTR change is detected in patients with other lung disorders.
The aim of this study was to investigate whether heterozygosity for CFTR mutations could be a determinant risk factor in the development of bronchiectasis in adult patients.
We have performed the CFTR gene analysis in a cohort of 55 bronchiectasis adult patients with unknown aetiology. The 5T variant, (TG)m and the M470V polymorphisms were also analyzed. A general population in which the same molecular analysis was previously performed was used as control group. The mutational spectrum of patients was also compared with that found in our CF population.
CFTR mutations/variants were found in 20 patients (36%), 14 with only one mutant gene (25%). contributing to the different CFTR-related phenotypes (13, 14) . In fact, the 5T variant has shown a high specificity in congenital bilateral absence of vas deferens (CBAVD) (15) .
We report here the complete analysis of the CFTR gene in a cohort of 55 adult patients with bronchiectasis of unknown aetiology. The aim of this study was to investigate whether CFTR mutations/variants, including the 5T-(TG)m-M470V polyvariant, are a determinant risk factor for the development of bronchiectasis in adult patients.
PATIENTS AND METHODS
Patients
Between 1994 and 2002, we recruited adult patients (≥ 18 years old) with bronchiectasis of unknown aetiology and normal sweat test for the CFTR gene study.
The diagnosis of bronchiectasis was confirmed by high-resolution computed tomography (HRCT) as previously described (16) . None of the patients fulfilled CF criteria. All patients had negative sweat tests (17) Fifty-five patients, 18 males (mean age 41.4 years, range 18-68) were included in this study. Two patients were sibs and another reported a second-degree relative with CF. All patients gave their informed written consent.
The CFTR mutations/variants found in this study were compared with those identified in the general population, partners of CF patients or carriers (n = 41) (12) .
Additionally, we compared the frequencies of the common CF mutations in the bronchiectasis group with that found in CF Spanish patients (19) .
CFTR gene analysis
Molecular analysis of the CFTR gene was performed in all 59 patients. Genomic DNA was isolated from peripheral blood lymphocytes using standard protocols (Promega, Wizard® Genomic DNA purification kit). After analysis of 31 common mutations in CF patients (PCR/OLA Applied Biosystems CF System), the whole coding region and intronic boundaries of the CFTR gene were analyzed using multiplex denaturing gradient gel electrophoresis (DGGE) (20) 
Statistical analysis
Statistical significance was evaluated by comparison between groups with the independent-samples T test and Levene's test for quantitative variables and the Fisher's exact 2-tailed test for qualitative traits, using the statistical analysis software package SPSS 8.0 (SPSS Inc., Chicago, IL). P values < 0.05 were considered to indicate statistical significance.
RESULTS
A total of fourteen mutations and two variants were identified in 20 patients (36%) with bronchiectasis (Table 1 ). There were no statistical differences in the clinical features as age, gender, bronchiectasis extension and pulmonary function test, between patients with and without CFTR mutations. However, presence of
Staphilococcus aureus in sputum (P = 0.001) and ABPA were observed among patients with mutations and/or variants ( Tables 1, 2 ).
F508del was the most common mutation, with a relative frequency of 25%.
One stop mutation (G542X) and one splice site mutation (2789+5G>A) were detected in two other patients. Overall, these mutations were detected in 7 patients (12.7%).
Taking into account their frequencies in Spanish CF patients (53.2%, 8.4% and 0.9%, respectively) (19) and assuming a 4% of CF carriers, the expected frequency of these mutations in the general population would be 2.5%, the frequency in bronchiectasis patients being significantly higher (P = 0.03).
Among the eleven missense mutations, the (G1237S) a G>A substitution at nucleotide 3841 is reported for the first time in this work and was detected in two sibs, the brother presenting oligozoospermia. In this patient, Young Syndrome was evaluated by means of scintigraphy to ciliary motility analysis and nasal mucus biopsy studied by electron microscopy. No alterations were found. Additionally, the patient was father of three children.
Moreover, two variants affecting normal CFTR synthesis (5T and 1716G/A) were found in 5 patients. The 1716G/A variant that changes the splice site consensus sequence leading to skipping of exon 10 (22) was identified in one patients (1.8%).
Another four patients (7.2%) carried the 5T variant (one of them homozygous) a similar frequency to that found in the general population (9.4%). This variant produces less splicing efficiency of exon 9, furthermore, a lower functional haplotype (5T-12TG-V470) was found in 3 out of 4 patients.
Eight patients had two CFTR changes, although it was not possible to determine if these changes corresponded to different alleles, we have found that they segregate independently in our CF families except the missense mutations G576A and R668C which occur on the same allele (26) . So, we have found six patients (10%) with both CFTR genes mutated. The remaining 14 patients (25%) had only one CFTR mutant gene.
Finally, analysis of M470V polymorphism in exon 10 showed the M470 allele in 58% of patients, being not significantly different to the frequency in the general population (63%) (12) . However, 90% of bronchiectasis patients with CFTR mutations had methionine (M) at this position, which is significantly different to the frequency observed in the general population (63%) (P = 0.01) or in bronchiectasis patients without CFTR mutations (40%) (P < 0.001).
DISCUSSION
We have performed clinical and molecular analysis in a series of 55 adult patients with bronchiectasis of unknown aetiology in order to investigate the role of the CFTR gene in this phenotype.
The mutational analysis performed led us to identify 20 patients (36%) with at least one CFTR mutation or variant. Previous reports (7) (8) (9) (10) (11) , showed a frequency of CFTR mutations ranging from 8% to 48%. In order to obtain a homogeneous group, criteria for inclusion in our series were restricted to adult patients (>18 years old)
suffering from bronchiectasis of unknown aetiology and without other features considered in the criteria for CF diagnosis (23) . Moreover, all samples from patients and controls were submitted to a complete CFTR gene analysis using the two most common screening techniques (DGGE and SSCP/HD) followed by direct sequencing of the regions with abnormal patterns.
CFTR mutations have been described in patients with ABPA (5, 6) and oligoazoospermia (24) , and it was not a surprise to find them in two and one, respectively, of our patients with CFTR changes. More interestingly, we found colonization for Staphilococcus aureus, which is frequent in CF patients (10) but rare in patients with bronquiectasis, (unless they posses a factor predisposing them to it) in six patients all of them with CFTR changes.
The mutational spectrum observed in adult patients with bronchiectasis differs considerably from that identified in the CF patients. Among the common mutations reported in Spanish CF families (19) , only three were detected in the bronchiectasis group (F508del, G542X, 2789+5G>A). This different spectrum is probably due to the missense mutations, which show a higher frequency in bronchiectasis patients (69%) than in CF Spanish patients (37%) (T. Casals unpublished data).
One of the most extensively studied regions of CFTR is the poly-T tract of intron 8, which produces transcripts skipping exon 9 (25) . Penetrance of the 5T variant depends on the (TG)m and M470V loci (13) . Patients with the 5T variant presented two different haplotypes, 5T-12TG-V470 (the most frequent in CBAVD)
and 5T-11TG-M470 or M/V (also identified on normal chromosomes). Controversial data on the role of the 5T variant in bronchiectasis patients have been reported.
Pignatti and coworkers (7) after analyzing 16 bronchiectasis patients suggested that the 5T variant had a similar role to that described in the CBAVD phenotype.
However, a second study did not detect a single case with the 5T variant out of 32 bronchiectasis patients studied (8) . In our analysis of 55 patients we have found a slightly lower frequency (7.2%) of the 5T variant than in the general population (9.4%) (12) but significantly different (P < 0.001) from that reported in CBAVD patients (43%) (26) . Consequently, we have discarded a predominant role of the 5T variant in bronchiectasis patients, however it was found in 4 patients.
We hypothesize a putative dominant effect of the CFTR mutations that could be associated with the presence of the M470 allele, which presents nearly twice the CFTR channel activity than the V470 allele (13) and was found over-represented (90%) among patients with CFTR changes. In fact, a similar frequency was found in a cohort of asthma (12) and rhinosinusitis (27) patients bearing CFTR mutations.
Little is known about most of missense mutations, especially that identified in normal chromosomes (4) . However, a recent study (28) has showed that the G576A mutation, among others missense changes, lead to exon 12 skipping and the proportion of aberrant transcripts increase when R668C mutation in exon 13 is also present. The authors describe exonic regulatory sequences involved in the splicing process. This finding point out that missense changes must be accurately analyzed, even if they have been found in normal chromosomes, because they could affect CFTR level expression.
In summary, our data suggest that heterozygosity (haploinsufficiency) for CFTR has pathogenic consequences, playing a role in the development of bronchiectasis in adult patients, probably with other genetic and epigenetic associated factors. Detailed epidemiological studies of subjects carrying CFTR mutations should be carried out in order to evaluate the importance of heterozygosity for CFTR mutations in CFTR-related phenotypes. 
